FAKnostics Fibrosis Therapeutics Program
Transforming the Fight Against Fibrosis with FAK Inhibition
Combating Liver Fibrosis & Cirrhosis
Over 1.5 billion people worldwide have some form of chronic liver disease, ultimately leading to liver fibrosis, or excessive accumulation of scar tissue. At FAKnostics, we are transforming this worldwide problem with our innovative FAK inhibitors.
Tackling IPF - A Stealthy Lung Disease
​With elusive causes and devastating consequences, IPF silently robs individuals of their breath and vitality. Our groundbreaking in-vivo studies are poised to deliver groundbreaking therapies, giving hope to those suffering from this insidious lung disease.
Scar Resolution - Unlocking New Possibilities
For far too long, patients have endured the burden of permanent scars and keloids. Together, we can rewrite the narrative, introducing innovative in-vitro approaches that pave the way for scarless healing and rejuvenation.
We have currently 3 pre-clinical programs in the application of our FAK inhibitor (FN-2012) to fibrotic diseases. Preliminary data in our targeting of the FAT domain of FAK show superior results in reducing Liver, Lung and Skin Fibrosis relative to the kinase-domain targeting.
FAKnostics Cancer Therapeutics Program
Cancer-selective cyclic peptides with high efficacy and safety that inhibit cancer progression
FN-2012 is our proprietary hydrocarbon-stapled peptide that effectively blocks the FAK FAT domain, offering a promising avenue for cancer treatment. FN-2012 possess remarkable properties, including enhanced alpha helicity, permeability, binding affinity, proteolytic resistance, and pharmacokinetic characteristics.
.png)
Targeting the FAK FAT Domain
Unlike traditional methods that target the kinase domain, we prioritize the FAK FAT domain due to its high sequence specificity and critical role regulating the focal adhesion complex, cancer metastasis, and apoptosis.
FAKnostics Innovation
Our patented first-in-class FAK FAT inhibitor has a unique mechanism of action, creating a drug with higher anti-tumor efficacy, higher specificity, and lower toxicity compared to 1st generation FAK inhibitors.
